Interferon-free hepatitis C therapy: How close are we?

Drugs

Volumn 72, Issue 14, 2012, Pages 1825-1831

  Pockros, Paul J ^a  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

ABT 072; ABT 333; ABT 450; Alisporivir; Asunaprevir; Balapiravir; BI 201335; BI 207127; BMS 986094; Boceprevir; Calcineurin inhibitors; Daclatasvir; Danoprevirritonavir; Erythropoietins; GS 5885; GS 9256; GS 9451; Hepatitis C; Hepatitis C protease inhibitors; Hepatitis C virus NS 5 protein inhibitors; Interferon alpha; Lomibuvir; Mericitabine; MK 5172; Peginterferon alfa; PSI 938; Ribavirin; Ritonavir; Setrobuvir; Simeprevir; Sofosbuvir; Tegobuvir; Telaprevir; Valopicitabine

Indexed keywords

ABT 072; ABT 333; ABT 450; ALISPORIVIR; ANA 598505; ANTIVIRUS AGENT; ASUNAPREVIR; BALAPIRAVIR; BI 207127; BMS 986094; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; GS 5885; GS 7977; GS 9256; GS 9451; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERFERON; INX 189; MERICITABINE; MK 5172; PEGINTERFERON; PSI 938; RIBAVIRIN; RITONAVIR; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VX 22;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); COMPENSATED LIVER CIRRHOSIS; COUGHING; CROSS RESISTANCE; DECOMPENSATED LIVER CIRRHOSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG INTERACTION; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENOTYPE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; PANCREATITIS; PARAMETERS; RASH; RELAPSE; REVIEW; SIDE EFFECT; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84866062357     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635560-000000000-00000     Document Type: Review

References (36)

1. Pockros PJ. Drugs in development for viral hepatitis: care and caution. Drugs 2011; 71 (3): 263-71
2. Hezode C, Dorival C, Zoulim F, ANRS CO20 CUPIC study group. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non re-sponders: first results of the French early access program (ANRS CO20-CUPIC) [abstract no. 8]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
3. Pockros PJ, Hunt D, Scherschel A. Preliminary results of twice daily dosing (Q12 hr) of telaprevir (TVR) for treatment naive and previously treated patients with genotype 1 HCV: comparable RVR, eRVR and SVR12 to standard daily dosing at Q8 hr [abstract no. 1830]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9-13; Boston (MA)
4. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16
5. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206
6. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17
7. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 1-12
8. Vertex Pharmaceuticals Inc. Highlights of prescribing information: INCIVEK™ (telaprevir) film coated tablets, for oral use. Cambridge (MA): Vertex Pharmaceuticals Incorporated, 2012 Jun [online]. Available from URL: http://pi.vrtx.com/files/uspi-telaprevir.pdf [Accessed 2012 Aug 22]
9. Merck Sharp & Dohme Corp. Highlights of prescribing information: VICTRELIS® (boceprevir) capsules for oral use. Whitehouse Station (NJ): Merck Sharp & Dohme Corp., [online]. Available from URL: http://www.merck.com/product/usa/pi-circulars/v/victrelis/victrelis-pi.pdf [Accessed Aug 22]
10. Mallolas J, Pol S, Rivero A, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected patients: end of treatment (week-48) interim results [abstract no 47]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
11. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. He-patology 2011; 54 (1): 20-7
12. Coilly A, Roche B, Botta-Fridlund D, et al. Efficacy and safety of protease inhibitors for severe hepatitis recurrence after liver transplantation: a first multicentric experience [LB abstract no. 1422]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
13. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/-riba-virin, in treatment-naive patients with chronic HCV GT1, 2, or 3 [abstract no. 1422]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
14. Janssen R&D Ireland. A phase II trial of TMC435 in combination with PSI-7977 in prior G1 null responders to Peg-IFN/RBV, hepatitis C-infected patients [ClinicalTrials.gov identifier NCT01466790]. US National Institutes of Health, ClinicalTrials.gov [online] Available from URL: http://www. clinicaltrials.gov [Accessed 2012 Aug 26]
15. Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012 Aug; 54 (4): 352-4
16. Chayama K, Takahashi S, Kawakami Y, et al. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders [abstract no. LB-4]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 2011 Nov 4-8; San Francisco (CA)
17. Lawitz E, Poordad F, Kowdley KV, et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCV IL28B-CC genotype-1-infected subjects [abstract no. 13]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
18. Poordad F, Lawitz E, Kowdley KV, et al. 12-Week interferon-free regimen of ABT-450/r+ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders [abstract no. 1399]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
19. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastro-enterology 2011 Dec; 141 (6): 2047-55
20. Gane EJ, Pockros P, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/R with or without ribavirin in treatment-naive HCV genotype 1-infected patients [abstract]. J Hepatology 2012; 56 (Suppl. 2): S555
21. Hoffmann-La Roche. ANNAPURNA: a study of the combination of RO5466731, RO5190591, ritonavir and Cope-gus (ribavirin) with or without RO5024048 in patients with chronic hepatitis C who are either treatment-naive or have previously experienced a null response to interferon-based treatment [ClinicalTrials.gov identifier NCT01628094]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Aug 26]
22. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/RBV for up to 28 days in treatment-naive, genotype 1 HCV subjects [abstract no. LB1]. 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010 Oct 29-Nov 2; Boston (MA)
23. Pawlotsky JM, Sarin SK, Foster G, et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study [abstract no. LB 11]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
24. Sulkowski M, Rodriguez-Torres M, Lawitz E, et al. High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results [abstract no. 1421]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
25. Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 Suppl. 1: S88-100
26. Sarrazin C, Zeuzem S. Resistance to directantiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010: 138; 447-62
27. Nelson DR, Gane EJ, Jacobson IM, et al. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR 12 interim analyses [abstract]. Hepatology 2011; 54: 1442
28. Gane EJ, Stedman C, Anderson J, et al. 100% rapid virologic response for PSI-7977+ribavirin in genotype 1 null responders (ELECTRON): early viral decline similar to that observed in genotype 1 and genotype 2/3 treatment-naive patients [abstract no. 54LB]. 19th Conference on Retroviruses and Opportunistic Infections; 2012 Mar 5-8; Seattle (WA)
29. Gane EJ, Stedman CA, Hyland RH, et al. Once daily PSI7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 [abstract no. 34]. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011); 2011 Nov 4-8; San Francisco (CA)
30. Gane EJ, Stedman CA, Hyland RH, et al. ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3 [abstract no. 1113]. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona
31. Bristol-Myers to suspend a drug study. New York Times 2012 Aug 3
32. Pockros PJ. New direct acting antivirals (DAAs) in development for HCV infection. Therap Adv Gastroenterol 2010 May; 3 (3): 191-202
33. Gilead Sciences, Inc. Gilead announces early sustained virologic response rates for GS-7977 plus ribavirin in genotype 1 treatment-naive hepatitis C patients: interim results reported from ELECTRON and QUANTUM studies [media release]. 2012 Apr 19 [online]. Available from URL: http://investors. gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle& ID=1684792&highlight=[Accessed 2012 Aug 21]
34. Pollack A. Collaboration on hepatitis C drugs lags. New York Times 2012 Apr 19
35. Gilead Sciences. GS-5885, GS-9451 with peginterferon alfa 2a (PEG) and ribavirin in treatment-naive subjects with chronic genotype 1 hep C virus infection and IL28B CC genotype [ClinicalTrials.gov identifier NCT01384383]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Aug 22]
36. Bristol-Myers Squibb. Phase 2b study of BMS-986094 and daclatasvir, with or without ribavirin for the treatment of patients with chronic hepatitis C [ClinicalTrials.gov identifier NCT01629732]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Aug 22]